These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35687792)

  • 1. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
    Buza N; Hui P
    Arch Pathol Lab Med; 2022 Jun; 146(5):0. PubMed ID: 35687792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 Status Assessment in Endometrial Serous Carcinoma: Comparative Analysis of Two Proposed Testing and Interpretation Algorithms.
    Hashem S; Zare SY; Fadare O
    Int J Gynecol Pathol; 2024 Jan; 43(1):4-14. PubMed ID: 37406350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
    Buza N; English DP; Santin AD; Hui P
    Mod Pathol; 2013 Dec; 26(12):1605-12. PubMed ID: 23765245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma.
    Sukov WR; Zhou J; Geiersbach KB; Keeney GL; Carter JM; Schoolmeester JK
    Hum Pathol; 2023 Jul; 137():94-101. PubMed ID: 37094656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic Features of 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 Breast Carcinoma (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0).
    Wilcock D; Sirohi D; Albertson D; Cleary AS; Coleman JF; Jedrzkiewicz J; Mahlow J; Ruano AL; Gulbahce HE
    Arch Pathol Lab Med; 2024 Aug; 148(8):890-897. PubMed ID: 37934954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
    Pu X; Shi J; Li Z; Feng A; Ye Q
    Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
    Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
    Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
    Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
    Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
    Buza N
    Int J Gynecol Pathol; 2021 Jan; 40(1):17-23. PubMed ID: 33290351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
    Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
    Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.
    Buza N
    Arch Pathol Lab Med; 2021 Jun; 145(6):687-691. PubMed ID: 32649220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?
    Wang M; Ding Q; Gu J; Sfamenos SM; Huo L; Tang Z; Sun H; Robinson M; Tang G; Lim B; Wu Y; Albarracin CT; Sahin AA; Chen H
    Clin Breast Cancer; 2023 Jun; 23(4):415-422. PubMed ID: 36878823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
    Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
    Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
    Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
    Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.